In February 2013, the FDA (Food and Drug Administration) of the US approved a new drug for the treatment of dyspareunia (painful sexual relations), caused by the thinning of the vulva and vaginal tissues in the menopausal time of life.
The drug is called Osphena (ospemifene), and it acts as a tissue selective estrogen protagonist and antagonist. This means that in some tissues, like the uterine lining and the vulva/vagina tissues, the ospemifene stimulates the tissue like estrogen, and in other tissues it acts like an anti-estrogen.
- This is a medication in the same family as tamoxifen, which is used in breast cancer treatment and prevention protocols.
- Dyspareunia is decreased because ospemifene has been shown to stimulate the vaginal mucosal tissue.
- Osphena is an oral tablet which is taken daily.
- It is contraindicated in patients with estrogen dependent cancers, a history of stroke or blood clots, or a cardiac history.
- With this medication, there has been a reported increase in hot flushes.
- This new medication may appeal to women who are not interested in using estrogen vaginal treatments or systemic hormone replacement therapy.
If you are suffering with this menopausal problem, speak to your health care professional because help is available, and this new medication may be an answer for you.